Register now
To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.
Already have an account?
If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.
The disease burden of COPD in Canada is significant. It is estimated to affect 2.0 million Canadians aged 35 and older, with COPD-related deaths occurring at a rate of 22.2 per 1,000 in 2011-2012.1
Key facts about exacerbations in COPD2
According to the CTS guidelines, COPD can result in a high burden of disease reflected in health status, morbidity, and mortality.
Data for BREZTRI AEROSPHERE on the rate of severe or moderate exacerbations, lung function, and health status (SGRQ) are presented elsewhere on this site. BREZTRI AEROSPHERE’s effect on hospitalization, morbidity, and mortality have not been evaluated as predefined endpoints in prospectively designed, well-controlled, randomized trials.
The CTS guidelines define a COPD exacerbation as an acute worsening of respiratory symptoms that may require the use of antibiotics, systemic corticosteroids, and/or healthcare services. The varying levels of exacerbation severity are:
Moderate
Prescription for an antibiotic and/or oral corticosteroids
Severe
Requires hospitalization or an emergency department visit
COPD: chronic obstructive pulmonary disease; CTS: Canadian Thoracic Society; SGRQ: St. George’s Respiratory Questionnaire.
References:
BREZTRI® and AEROSPHERE® are registered trademarks of AstraZeneca AB, all used under license by AstraZeneca Canada Inc.
